Aktieanalys

Ultimovacs Q1 2023: Patience is a virtue - Redeye

{newsItem.title}

Redeye Publicerad: 11 May 2023 07:31

Redeye provides its comment on Ultimovacs’ Q1 2023 report, which featured no surprises. We consider the imminent INITIUM and NIPU readouts, expected in 2023e, to constitute critical potential value inflection points for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/905774/ultimovacs-q1-2023-patience-is-a-virtue?utm_source=finwire&utm_medium=RSS

Nyheter om Ultimovacs

Läses av andra just nu

Om aktien Ultimovacs

Senaste nytt